{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:22:20Z","timestamp":1778656940109,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12328-020-01134-3","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T14:03:23Z","timestamp":1590674603000},"page":"891-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma"],"prefix":"10.1007","volume":"13","author":[{"given":"Tomoko","family":"Adachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-0480","authenticated-orcid":false,"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Nagamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Izumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Aibiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Okudaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroka","family":"Yamago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichiro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Suga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Michitaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"1134_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1134_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure\/refractoriness: JSH\u2013LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22\u201331.","journal-title":"Oncology"},{"key":"1134_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000365993","volume":"87","author":"S Ogasawara","year":"2014","unstructured":"Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87:330\u201341.","journal-title":"Oncology"},{"key":"1134_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000367743","volume":"4","author":"T Arizumi","year":"2015","unstructured":"Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4:253\u201362.","journal-title":"Liver Cancer"},{"issue":"Suppl 1","key":"1134_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000481241","volume":"93","author":"C Ogawa","year":"2017","unstructured":"Ogawa C, Morita M, Omura A, et al. Hand\u2013foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. Oncology. 2017;93(Suppl 1):113\u20139.","journal-title":"Oncology"},{"key":"1134_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458\u201368.","journal-title":"Liver Cancer"},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1134_CR8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/hepr.13243","volume":"49","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49:111\u20137.","journal-title":"Hepatol Res"},{"key":"1134_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"1134_CR10","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S1470-2045(19)30165-2","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Finn RS, Galle PR, et al. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein. Lancet Oncol. 2019;20:e191.","journal-title":"Lancet Oncol"},{"key":"1134_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1159\/000480256","volume":"35","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka A, Kumada T, Kudo M, et al. Hepatic function during repeated tace procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig Dis. 2017;35:602\u201310.","journal-title":"Dig Dis"},{"key":"1134_CR12","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2018.36.15_suppl.4018","volume":"36","author":"M Peck-Radosavljevic","year":"2018","unstructured":"Peck-Radosavljevic M, Kudo M, Raoul J, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis. J Clin Oncol. 2018;36:4018.","journal-title":"J Clin Oncol"},{"key":"1134_CR13","first-page":"47","volume":"25","author":"BX Yan","year":"2018","unstructured":"Yan BX, Zheng YX, Li W, et al. Comparative expression of PEDF and VEGF in human epidermal keratinocytes and dermal fibroblasts: from normal skin to psoriasis. Discov Med. 2018;25:47\u201356.","journal-title":"Discov Med"},{"key":"1134_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1517\/13543784.2012.636351","volume":"21","author":"AA Crawshaw","year":"2012","unstructured":"Crawshaw AA, Griffiths CE, Young HS. Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs. 2012;21:33\u201343.","journal-title":"Expert Opin Investig Drugs"},{"key":"1134_CR15","first-page":"677","volume":"30","author":"EA Antoniou","year":"2016","unstructured":"Antoniou EA, Koutsounas I, Damaskos C, et al. Remission of psoriasis in a patient with hepatocellular carcinoma treated with sorafenib. Vivo. 2016;30:677\u201380.","journal-title":"Vivo"},{"key":"1134_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jdcr.2018.09.009","volume":"4","author":"MS van Kester","year":"2018","unstructured":"van Kester MS, Luelmo SAC, Vermeer MH, et al. Remission of psoriasis during treatment with sorafenib. JAAD Case Rep. 2018;4:1065\u20137.","journal-title":"JAAD Case Rep"},{"key":"1134_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4103\/0019-5154.127668","volume":"59","author":"A Datta-Mitra","year":"2014","unstructured":"Datta-Mitra A, Riar NK, Raychaudhuri SP. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol. 2014;59:632.","journal-title":"Indian J Dermatol"},{"key":"1134_CR18","first-page":"169","volume":"9","author":"ML Diamantis","year":"2010","unstructured":"Diamantis ML, Chon SY. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol. 2010;9:169\u201371.","journal-title":"J Drugs Dermatol"},{"key":"1134_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4103\/0378-6323.84089","volume":"77","author":"MA Gonzalez-Lopez","year":"2011","unstructured":"Gonzalez-Lopez MA, Gonzalez-Vela MC, Yanez S, et al. Psoriasiform skin eruption associated with sorafenib therapy. Indian J Dermatol Venereol Leprol. 2011;77:614\u20135.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1134_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/j.1346-8138.2012.01615.x","volume":"39","author":"CT Hung","year":"2012","unstructured":"Hung CT, Chiang CP, Wu BY. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy. J Dermatol. 2012;39:1076\u20137.","journal-title":"J Dermatol"},{"key":"1134_CR21","first-page":"301","volume":"85","author":"V Laquer","year":"2010","unstructured":"Laquer V, Saedi N, Dann F, et al. Sorafenib-associated psoriasiform skin changes. Cutis. 2010;85:301\u20132.","journal-title":"Cutis"},{"key":"1134_CR22","first-page":"899","volume":"13","author":"T Ilknur","year":"2014","unstructured":"Ilknur T, Akarsu S, Carsanbali S, et al. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. J Drugs Dermatol. 2014;13:899\u2013900.","journal-title":"J Drugs Dermatol"},{"key":"1134_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.dsi.2016.01.004","volume":"34","author":"M Hsu","year":"2016","unstructured":"Hsu M, Chen C. Psoriasis flare-ups following sorafenib therapy: a rare case. Dermatologica Sinica. 2016;34:148\u201350.","journal-title":"Dermatologica Sinica"},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/LGT.0000000000000220","volume":"20","author":"EL Bourne","year":"2016","unstructured":"Bourne EL, Day T, Scurry J. Regorafenib-associated vulvar psoriasiform skin reaction: case of the month from the ISSVD case consultation committee. J Low Genit Tract Dis. 2016;20:e44\u201345.","journal-title":"J Low Genit Tract Dis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-020-01134-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T01:38:11Z","timestamp":1622165891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-020-01134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01134-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Conflicts of interest of Dr. Atsushi Hiraoka (2018\u20132019). Lecture: Eisai, Bayer, Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}